EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis

Scott H Donaldson, Timothy E Corcoran, Joseph M Pilewski, Peter Mogayzel, Beth L Laube, Evan R Boitet, Elex S Harris, Agathe Ceppe, Lloyd J Edwards, Kirby Zeman, Jihong Wu, Charles R Esther und 3 weitere

Journal of Cystic Fibrosis · 2024-01 · 23 (1) · 155-160

DOI: 10.1016/j.jcf.2023.10.010 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Cystic Fibrosis, 2024-01. Verfasst von Scott H Donaldson und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Univ. North Carolina at Chapel Hill, USA. Electronic address: scott_donaldson@med.unc.edu. Hauptthemen laut MEDLINE: Cystic Fibrosis, Indoles, Pyrazoles, Pyridines. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIEHS NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The cystic fibrosis transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (E/T/I) is highly effective clinically for those with at least one F508del-CFTR allele. The effects of E/T/I on mucociliary clearance (MCC) and sputum properties are unknown. We, therefore, sought to characterize the effects of E/T/I on in vivo MCC and sputum characteristics hypothesized to impact mucus transport. METHODS: Forty-four participants ≥12 years of age were enrolled into this prospective, observational trial prior to initiation of E/T/I and had baseline measurement of MCC and characterization of induced sputum and exhaled breath condensate (EBC) samples. Study procedures were repeated after 1 month of E/T/I treatment. RESULTS: Average age was 27.7 years with baseline forced expiratory volume in 1 second (FEV1) of 78.2 % predicted. 52 % of subjects had previously been treated with a 2-drug CFTR modulator combination. The average whole lung MCC rate measured over 60 min (WLAveClr60) significantly improved from baseline to post-E/T/I (14.8 vs. 22.8 %; p = 0.0002), as did other MCC indices. Sputum% solids also improved (modeled mean 3.4 vs. 2.2 %; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisIndolesPyrazolesPyridinesPyrrolidinesQuinolonesHumansAdultCystic Fibrosis Transmembrane Conductance RegulatorMucociliary ClearanceProspective StudiesAminophenolsBenzodioxolesMucusMutationChloride Channel Agonists

Stichwörter der Autor:innen

Cystic fibrosisElexacaftorModulatorMucociliary clearanceRheologymucus

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorelexacaftorivacaftortezacaftorAminophenolsBenzodioxolesChloride Channel AgonistsIndolesPyrazolesPyridines

Autor:innen und Institutionen

  • Department of Medicine, Univ. North Carolina at Chapel Hill, USA. Electronic address: scott_donaldson@med.unc.edu.
  • Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, USA.
  • Pediatric Pulmonary Medicine, Johns Hopkins University, USA.
  • Department of Medicine and the Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, USA.
  • Department of Medicine, Univ. North Carolina at Chapel Hill, USA.
  • Department of Biostatistics, University of Alabama at Birmingham, USA.

Förderung

  • NIDDK NIH HHS
  • NIEHS NIH HHS
  • NCATS NIH HHS
  • Cystic Fibrosis Foundation
  • AstraZeneca
  • BHF Centre of Research Excellence, Oxford
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Donaldson, S. H., Corcoran, T. E., Pilewski, J. M., Mogayzel, P., Laube, B. L., Boitet, E. R., Harris, E. S., Ceppe, A., Edwards, L. J., Zeman, K., Wu, J., Esther, C. R., Nichols, D. P., Bennett, W. D., & Rowe, S. M. (2024). Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis. Journal of Cystic Fibrosis, 23(1), 155-160. https://doi.org/10.1016/j.jcf.2023.10.010

Vancouver

Donaldson SH, Corcoran TE, Pilewski JM, Mogayzel P, Laube BL, Boitet ER, et al. Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis. Journal of Cystic Fibrosis. 2024;23(1):155-160. doi:10.1016/j.jcf.2023.10.010

BibTeX
@article{Donaldson2024,
  author = {Donaldson, Scott H and Corcoran, Timothy E and Pilewski, Joseph M and Mogayzel, Peter and Laube, Beth L and Boitet, Evan R and Harris, Elex S and Ceppe, Agathe and Edwards, Lloyd J and Zeman, Kirby and Wu, Jihong and Esther, Charles R and Nichols, David P and Bennett, William D and Rowe, Steven M},
  title = {Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2024},
  volume = {23},
  number = {1},
  pages = {155--160},
  doi = {10.1016/j.jcf.2023.10.010}
}
Kostenlos starten →